Therapeutic area | EBAs (n) | Assessments in analysis set (n) | Main reason for EBAs not being evaluablea | |||
---|---|---|---|---|---|---|
Included | Excluded | No dossier submitted | Data on PEP acceptance by G-BA not evaluable | Newer assessment available (same medicine and indication) | ||
Oncological diseases | 47 | 36 | 11 | 2 | 6 | 3 |
Metabolic diseases | 34 | 15 | 19 | 3 | 14 | 2 |
Infectious diseases | 16 | 14 | 2 | 0 | 2 | 0 |
Total | 97 | 65 | 32 | 5 | 22 | 5 |